Australia Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Australia drug delivery devices market size in 2026 is estimated at USD 4.97 billion, growing from 2025 value of USD 4.59 billion with 2031 projections showing USD 7.36 billion, growing at 8.20% CAGR over 2026-2031. This report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps and More), Route of Administration (Injectable, Inhalational, Transdermal and More), Application (Cancer, Cardiovascular, Diabetes and More), End User (Hospitals, Ambulatory Surgical Centers, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Australia Drug Delivery Devices Market Trends and Insights

High Burden of Chronic Diseases and Ageing Population

Australia’s 1.3 million people living with diabetes in 2024 generated AUD 3.9 billion in direct health spending aihw.gov.au. Three-quarters of adults were dispensed at least one PBS medicine, and more than 85% of those with chronic conditions required ongoing pharmacotherapy.Age-related physiological changes alter drug absorption and clearance, heightening demand for delivery formats that optimise dosing precision and safety. Manufacturers that tailor devices to geriatric needs - larger buttons, audible cues, and connected adherence alerts - stand to gain as the senior cohort expands.

Government and Market Players Support for At-home Care & Remote Drug Delivery

Victoria’s Better at Home program channels AUD 698 million into virtual and in-home healthcare, serving more than 15,000 people a year. Queensland added AUD 27 million for similar services in its 2024-25 budget. Hospital-at-home models have lowered care costs by 30% while maintaining or improving outcomes, leading payers to reimburse home episodes at inpatient rates commonwealthfund.org. These policies create fertile ground for self-use injectors, wearable pumps, and connected inhalers that help patients manage therapy outside acute facilities.

Stringent TGA Combination-Product Compliance Costs

Application fees for new chemical entities included in a device run to AUD 18,872, with evaluation charges of AUD 76,055 and annual levies topping AUD 1,500 for Class III devices. These rising costs weigh heavily on start-ups and academic spin-outs, delaying market entry and, in some cases, redirecting R&D overseas.

Other drivers and restraints analyzed in the detailed report include:

• Rising Penetration of Biosimilars and Targeted Therapies Requiring Novel Delivery Formats
• Digital Health Integration with Connected Injectors & Pumps
• Needlestick Injury Litigation and Risks Associated with Various Devices

Segment Analysis

Injectable systems held 31.10% of the Australia drug delivery devices market share in 2025, a position cemented by growing biologics use and rising chronic-disease prevalence. Connected pen injectors that transmit dosage logs to clinician dashboards are gaining traction among endocrinologists and rheumatologists. The Australia drug delivery devices market size attached to transdermal patches is projected to grow at 11.92% CAGR between 2026 and 2031, spurred by microneedle breakthroughs that improve payload capacity without compromising comfort. Collaboration between the Transdermal and Transmucosal Drug Delivery Research Group and Bionyeri Pty Ltd created a microneedle patch for acute pain episodes, illustrating domestic innovation.

Infusion-pump makers are integrating Bluetooth and closed-loop algorithms in anticipation of a national subsidy for insulin pumps proposed to begin mid-2025. Implantables, ocular inserts, and nasal devices round out the portfolio, each targeting niche clinical requirements. A recent health-technology assessment found intrathecal pumps improve quality of life for refractory cancer pain, though upfront costs remain high.

Injectables delivered 44.10% of 2025 revenue within the Australia drug delivery devices market. High therapy adherence rates and predictable pharmacokinetics keep parenteral administration the default for many biologics. Inhalation devices account for a sizeable fraction, supported by ongoing upgrades to dry-powder carriers for obstructive-airway disease. The oral-mucosal channel is forecast to post a 10.05% CAGR as developers exploit sublingual routes to bypass first-pass metabolism.

Transdermal technologies continue to benefit from work on novel permeation enhancers and herbal patches that reduce gastrointestinal side effects. Nasal formulations appeal to neurologists for rapid central-nervous-system access; nanoparticle-gel hybrids recently showed 86%-96% encapsulation efficiency, signalling commercial promise.

Complete Report Scope:

• By Device Type
  • Injectable Delivery Devices
  • Inhalation Delivery Devices
  • Infusion Pumps
  • Transdermal Patches
  • Implantable Drug Delivery Systems
  • Ocular Inserts & Delivery Implants
  • Nasal & Buccal Delivery Devices
• By Route of Administration
  • Injectable
  • Inhalation
  • Transdermal
  • Oral Mucosal (Buccal & Sublingual)
  • Ocular
  • Nasal
• By Application
  • Cancer
  • Cardiovascular
  • Diabetes
  • Infectious Diseases
  • Other Applications
• By End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Home Healthcare Settings
  • Specialty Clinics
  • Other End Users

List of Companies Covered in this Report:

• Beckton Dickinson
• GlaxoSmithKline
• Novartis
• Terumo
• Novo Nordisk
• Johnson & Johnson (Johnson MedTech & Janssen)
• Sanofi
• Pfizer
• AstraZeneca
• Viatris
• Teva Pharmaceutical Industries
• Bayer
• Medtronic
• Insulet
• Tandem Diabetes Care
• Roche
• West Pharmaceutical Services
• Gerresheimer
• Ypsomed
• B. Braun Australia Pty Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support